Drugs against SARS-CoV-2: What do we know about their mode of action?
Journal
Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
19
05
2020
revised:
23
06
2020
accepted:
24
06
2020
pubmed:
12
8
2020
medline:
15
12
2020
entrez:
12
8
2020
Statut:
ppublish
Résumé
The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action.
Identifiants
pubmed: 32779326
doi: 10.1002/rmv.2143
pmc: PMC7435512
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Subventions
Organisme : European Union's Horizon 2020 research and innovation programme
ID : 101003627
Pays : International
Organisme : SCORE project H2020 SC1-PHE-Coronavirus194 2020
ID : 101003627
Pays : International
Organisme : Fondation pour la Recherche Médicale
Pays : International
Organisme : Inserm
Pays : International
Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
J Virol. 2018 Apr 27;92(10):
pubmed: 29514901
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723
pubmed: 32226289
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Int J Antimicrob Agents. 2020 Aug;56(2):106028
pubmed: 32450198
Antimicrob Agents Chemother. 2002 Apr;46(4):977-81
pubmed: 11897578
Pediatr Res. 2007 Oct;62(4):483-8
pubmed: 17667842
Nature. 2005 Aug 18;436(7053):967-72
pubmed: 16107837
Nat Rev Microbiol. 2015 Jul;13(7):426-37
pubmed: 26075364
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Antiviral Res. 2014 Apr;104:153-5
pubmed: 24462697
J Virol. 2019 Nov 26;93(24):
pubmed: 31578288
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Eur Respir J. 2010 Sep;36(3):646-54
pubmed: 20150207
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Viruses. 2018 Feb 09;10(2):
pubmed: 29425176
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Lancet Digit Health. 2020 Jun;2(6):e286-e287
pubmed: 32363333
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E162-E171
pubmed: 29279395
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
mBio. 2015 May 26;6(3):e00638-15
pubmed: 26015500
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
Antiviral Res. 2014 May;105:17-21
pubmed: 24583123
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Antiviral Res. 2013 Sep;99(3):301-6
pubmed: 23769930
Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80
pubmed: 22809499
J Virol. 2015 Feb;89(4):1954-64
pubmed: 25428871
Lancet. 2003 Jul 26;362(9380):293-4
pubmed: 12892961
PLoS Negl Trop Dis. 2016 May 10;10(5):e0004695
pubmed: 27163257
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Virus Res. 2015 Apr 16;202:120-34
pubmed: 25445340
J Virol. 2004 Jun;78(12):6134-42
pubmed: 15163706
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Emerg Infect Dis. 2004 Feb;10(2):317-9
pubmed: 15030704
J Biol Regul Homeost Agents. 2020 Mar 31;34(2):333-338
pubmed: 32228825
J Infect Dis. 2005 Feb 15;191(4):507-14
pubmed: 15655773
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
pubmed: 19321428
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
Eur Heart J. 2020 May 14;41(19):1801-1803
pubmed: 32196087
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
JAMA. 2020 Jul 14;324(2):168-177
pubmed: 32558877
J Virol. 2010 Dec;84(24):12658-64
pubmed: 20926566
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Nature. 2020 Jun;582(7813):469
pubmed: 32546811
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8
pubmed: 17620608
Int J Antimicrob Agents. 2020 Aug;56(2):106053
pubmed: 32534189
J Lab Clin Med. 2004 Jul;144(1):18-26
pubmed: 15252403
Antiviral Res. 2013 Dec;100(3):662-72
pubmed: 24161512
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Exp Physiol. 2008 May;93(5):543-8
pubmed: 18448662
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):206-214
pubmed: 28003465
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
Nat Med. 2000 Dec;6(12):1375-9
pubmed: 11100123
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Sci Rep. 2013;3:1686
pubmed: 23594967
Biochem Pharmacol. 2017 Nov 15;144:90-99
pubmed: 28789938
Nat Rev Microbiol. 2019 Oct;17(10):593-606
pubmed: 31341272
PLoS Pathog. 2013 Aug;9(8):e1003565
pubmed: 23966862
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Antiviral Res. 2006 Aug;71(1):53-63
pubmed: 16621037
Rev Med Virol. 2020 Nov;30(6):1-10
pubmed: 32779326
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):184-189
pubmed: 32362644
Lancet. 2000 Mar 4;355(9206):827-35
pubmed: 10711940
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653
Vopr Virusol. 2008 Jul-Aug;53(4):9-13
pubmed: 18756809
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
PLoS Med. 2018 Mar 27;15(3):e1002535
pubmed: 29584730
Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8
pubmed: 15351731
Antiviral Res. 2005 Jun;66(2-3):99-102
pubmed: 15911026
J Immunol. 2005 Apr 15;174(8):4908-15
pubmed: 15814718
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Curr Opin Virol. 2019 Apr;35:57-62
pubmed: 31125806
J Infect Dis. 2004 Apr 1;189(7):1164-7
pubmed: 15031783
J Biomol Screen. 2001 Dec;6(6):429-40
pubmed: 11788061
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
J Antimicrob Chemother. 2014 Oct;69(10):2770-84
pubmed: 24951535
Sci Rep. 2020 Aug 4;10(1):13093
pubmed: 32753646
Am J Med. 2015 Dec;128(12):1362.e1-6
pubmed: 26291905
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41
pubmed: 14983044
Vet J. 2005 Sep;170(2):193-211
pubmed: 16129340
Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25
pubmed: 15144898
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Life Sci Alliance. 2020 Jul 23;3(9):
pubmed: 32703818
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508